Literature DB >> 7444070

A comparison of methods for assessing patient body burden following 131I therapy for thyroid cancer.

S R Thomas, H R Maxon, K M Fritz, J G Kereiakes, W D Connell.   

Abstract

The effectiveness of three methods of assessing the patient body burden following 131I therapy was compared: (a) urine assay, (b) external exposure rate measurements, and (c) predictions based on a pretherapy diagnostic work-up. The urine assay method exhibited the greatest potential for error and personnel risk. The diagnostic work-up provided predictions of the body burden as a function of time, which may be applied to estimate the expected hospital stay. The direct external exposure rate survey showed the potential for being an accurate, reliable, and relatively safe method of monitoring the patient body burden.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7444070     DOI: 10.1148/radiology.137.3.7444070

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  4 in total

1.  Measurement of the radioactive body burden in patients receiving iodine-131 treatment for carcinoma of the thyroid.

Authors:  R Ravichandran; S S Supe; U Jayasree; S Devaru
Journal:  Eur J Nucl Med       Date:  1997-04

2.  Toxicity from treatment of neuroblastoma with 131I-meta-iodobenzylguanidine.

Authors:  J C Sisson; R J Hutchinson; J E Carey; B Shapiro; J W Johnson; S A Mallette; D M Wieland
Journal:  Eur J Nucl Med       Date:  1988

3.  Estimation of effective half life of clearance of radioactive Iodine (I) in patients treated for hyperthyroidism and carcinoma thyroid.

Authors:  R Ravichandran; Jp Binukumar; Amal Al Saadi
Journal:  Indian J Nucl Med       Date:  2010-04

4.  The study of external dose rate and retained body activity of patients receiving 131I therapy for differentiated thyroid carcinoma.

Authors:  Haiying Zhang; Ling Jiao; Songye Cui; Liang Wang; Jian Tan; Guizhi Zhang; Yajing He; Shuzhou Ruan; Saijun Fan; Wenyi Zhang
Journal:  Int J Environ Res Public Health       Date:  2014-10-21       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.